Aequus Pharmaceuticals Inc. is a Vancouver-based company, focused on enhancing delivery methods for approved drugs and select consumer products.
Aequus is a specialty pharmaceutical company primarily focused on the development and commercialization of long-acting alternatives to currently approved drugs, that are limited by non-compliance, high frequency dosing, first-pass metabolism side effects, painful injections, or where the commercial presentation can be improved by making a long acting alternative available. The Company’s initial product candidates are focused around Central Nervous System (“CNS”) disorders, where non-compliance with use and dosage instructions has particularly severe consequences to patients. Aequus’ lead product candidate, AQS-1301, is a once-weekly transdermal formulation of aripiprazole that is expected to enter Proof of Concept clinical trials mid 2015.
To learn more about Aequus visit their website at http://www.aequuspharma.ca/